Characterization of two pharmacophores on the multidrug transporter P-glycoprotein

Molecular Pharmacology

Volumn 62, Issue 6, 2002, Pages 1288-1298

  Garrigues, Alexia ^a,d   Loiseau, Nicolas ^b,d   Delaforge, Marcel ^b,d   Ferté, Jacques ^a,d   Garrigos, Manuel ^a,d   André, François ^c,d   Orlowski, Stéphane ^a,d,e  

^a Departement de Biologie Joliot Curie   (France)

^b Departement de Recherche Medicale   (France)

^c Departement de Biologie Joliot Curie   (France)

^d CNRS   (France)

^e DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE MAGNESIUM; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOLEUCYLPHENYLALANINE; CYCLOPEPTIDE; CYCLOSPORIN A; DACTINOMYCIN; EGTAZIC ACID; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; OUABAIN; PROGESTERONE; SODIUM AZIDE; TENTOXIN; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ARTICLE; BINDING SITE; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENZYME ASSAY; ENZYME SUBSTRATE; FIBROBLAST CULTURE; HYDROPHOBICITY; MEMBRANE VESICLE; MOLECULAR MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL;

ANIMALS; BINDING SITES; CELLS, CULTURED; CRICETINAE; HYDROPHOBICITY; MODELS, MOLECULAR; P-GLYCOPROTEIN; PEPTIDES, CYCLIC; PROTEIN CONFORMATION; STATISTICS;

EID: 0036893219     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.6.1288     Document Type: Article

References (48)

1. Ayesh S, Shao YM, and Stein WD (1996) Cooperative, competitive and noncompetitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316:8-18.
2. Biedler JL and Riehm H (1970) Cellular resistance to actinomycin D in chinese hamster cells in vitro: Cross-resistance, radioautographic and cytogenetic studies. Cancer Res 30:1174-1184.
3. Boer R, Dichtl M, Borchers C, Ulrich WR, Marecek JF, Prestwich GD, Glossmann H, and Striessnig J (1996) Reversible labeling of a chemosensitizer binding domain of P-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor. Biochemistry 35:1387-1396.
4. Borgnia MJ, Eytan GD, and Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163-3171.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Ecker G, Huber M, Schmid D, and Chiba P (1999) The importance of a nitrogene atom in modulators of multidrug resistance. Mol Pharmacol 56:791-796.
7. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan L-B, Yasuda K, Shepard RL, Winter MA, Schuetz JD, et al. (2002a) Application of three-dimentional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974-981.
8. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan L-B, Yasuda K, Shepard RL, Winter MA, Schuetz JD, et al. (2002b) Three-dimentional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61:964-973.
9. 3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49:1851-1861.
10. Ferté J (2000) Analysis of the tangled relationships between P-glycoproteinmediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 267:277-294.
11. Foxwell BM, Mackie A, Ling V, and Ryffel B (1989) Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 36:543-546.
12. Garrigos M, Belehradek J Jr, Mir LM, and Orlowski S (1993) Absence of cooperativity for MgATP and verapamil effects on the ATPase activity of P-glycoprotein containing membrane vesicles. Biochem Biophys Res Commun 196:1034-1041.
13. Garrigos M, Mir LM, and Orlowski S (1997) Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase: Further experimental evidence for a multisite model. Eur J Biochem 244:664-673.
14. Gilon C, Halle D, Chorev M, Selinger Z, and Byk G (1991) Backbone cyclization: A new method for conferring conformational constraint on peptides. Biopolymers 31:745-750.
15. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance by the multidrug transporter. Annu Rev Biochem 62:385-427.
16. Granveau-Renouf S, Valente D, Durocher A, Grognet JM, and Ezan E (2000) Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum. Eur J Drug Metab Pharmacokinet 25:79-84.
17. Klopman G, Shi LM, and Ramu A (1997) Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol 52:323-334.
18. Litman T, Zeuthen T, Skovsgaard T, and Stein WD (1997a) Competitive, noncompetitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1361:169-176.
19. Litman T, Zeuthen T, Skovsgaard T, and Stein WD (1997b) Structure-activity relationships of P-glycoprotein interacting drugs: Kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1361:159-168.
20. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, and Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-632.
21. Moriguchi I, Hirono S, Liu Q, Nakagome I, and Matsushita Y (1992) Simple method of calculation octanol/water partition coefficient. Chem Pharm Bull 40:127-139.
22. Naito M and Tsuruo T (1989) Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res 49:1452-1455.
23. Orlowski S and Garrigos M (1999) Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: Molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. Anticancer Res 19:3109-3124.
24. Orlowski S, Mir LM, Belehradek J Jr, and Garrigos M (1996) Effects of steroids and verapamil on P-glycoprotein ATPase activity: Progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J 317:515-522.
25. Orlowski S, Valente D, Garrigos M, and Ezan E (1998) Bromocriptine modulates P-glycoprotein function. Biochem Biophys Res Commun 244:481-488.
26. Osterberg T and Norinder U (2000) Theoretical calculation and prediction of Pglycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. Eur J Pharmaceut Sci 10:295-303.
27. Pascaud C, Garrigos M, and Orlowski S (1998) Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J 333:351-358.
28. A with P-glycoprotein in human intestinal epithelial cells. Eur J Pharmacol 288:187-192.
29. Pinet E, Neumann JM, Dahse I, Girault G, and André F (1995) Multiple interconverting conformers of the cyclic tetrapeptide tentoxin, [cyclo-(L-MeAla1-L-Leu2-MePhe[(Z) delta]3-Gly4)], as seen by two-dimensional 1H-nmr spectroscopy. Biopolymers 36:135-152.
30. Rao US and Scarborough GA (1994) Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol 45:773-776.
31. Saeki T, Ueda K, Tanigawara Y, Hori R, and Komano T (1993) Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077-6080.
32. Safa AR (1988) Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 85:7187-7191.
33. 1-ATPase: A model for the overactivation process. J Biol Chem 274:849-858.
34. Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8:161-170.
35. Schinkel AH, Wagenaar E, Mol CAAM, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97:2517-2524.
36. Schmid D, Ecker G, Kopp S, Hitzler M, and Chiba P (1999) Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol 58:1447-1456.
37. Schumacher MA, Miller MC, Grkovic S, Brown MH, Skurray RA, and Brennan RG (2001) Structural mechanisms of QacR induction and multidrug recognition. Science (Wash DC) 294:2158-2163.
38. Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252-261.
39. Shapiro AB, Fox K, Lam P, and Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone: Evidence for a third drug-binding site. Eur J Biochem 259:841-850.
40. Shapiro AB and Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130-137.
41. Sharom FJ, Yu X, Di Diodato G, and Chu JWK (1996) Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J 320:421-428.
42. Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, and Dantzig AH (1998) Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol 56:719-727.
43. Stein WD (1997) Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 77:545-590.
44. Tamai I and Safa AR (1991) Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 266:16796-16800.
45. Twentyman PR, Fox NE, and White DJG (1987) Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 56:55-57.
46. Wang E, Casciano CN, Clement RP, and Johnson WW (2000) Two transport binding sites of P-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim Biophys Acta 1481: 63-74.
47. Wiese M and Pajeva IK (2001) Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 8:685-713.
48. Zamora JM, Pearce HL, and Beck WT (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33:454-462.